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Endocrine Role of the Renin–Angiotensin System in Human
Adipose Tissue and Muscle
Effect of !-Adrenergic Stimulation
Gijs H. Goossens, Johan W.E. Jocken, Ellen E. Blaak, Paul M. Schiffers,
Wim H.M. Saris, Marleen A. van Baak
Abstract—The renin–angiotensin system has been implicated in obesity-related hypertension and insulin resistance. We
examined whether locally produced components of the renin–angiotensin system in adipose tissue and skeletal muscle
play an endocrine role in vivo in humans. Furthermore, the effects of !-adrenergic stimulation on plasma concentrations
and tissue release of renin–angiotensin system components were investigated. Systemic renin–angiotensin system
components and arteriovenous differences of angiotensin II (Ang II) and angiotensinogen (AGT) across abdominal
subcutaneous adipose tissue and skeletal muscle were assessed in combination with measurements of tissue blood flow
before and during systemic !-adrenergic stimulation in 13 lean and 10 obese subjects. Basal plasma Ang II and AGT
concentrations were not significantly different between lean and obese subjects. Ang II concentrations were increased
in obese compared with lean subjects during !-adrenergic stimulation (12.6!1.5 versus 8.1!1.0 pmol/L; P"0.04),
whereas AGT concentrations remained unchanged. Plasma renin activity increased to a similar extent in lean and obese
subjects during !-adrenergic stimulation (both P#0.01). No net Ang II release across adipose tissue and skeletal muscle
could be detected in both groups of subjects. However, AGT was released from adipose tissue and muscle during
!-adrenergic stimulation in obese subjects (both P#0.05). In conclusion, locally produced Ang II in adipose tissue and
skeletal muscle exerts no endocrine role in lean and obese subjects. In contrast, AGT is released from adipose tissue and
muscle in obese subjects during !-adrenergic stimulation, which may contribute to the increased plasma Ang II
concentrations during !-adrenergic stimulation in obese subjects. (Hypertension. 2007;49:542-547.)
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Abdominal obesity plays a central role in the metabolicsyndrome and is a major risk factor for chronic diseases,
such as type 2 diabetes mellitus and cardiovascular disease.1
Although abdominal obesity is frequently accompanied by
hypertension, the mechanisms by which an excess fat mass
may lead to hypertension are not fully understood. The renin–
angiotensin system (RAS) has been established as a major
determinant of blood pressure and cardiovascular disease.2
Furthermore, recent clinical trials suggest that blockade of
RAS may reduce the incidence of type 2 diabetes.3 Angio-
tensin II (Ang II), the main effector component of RAS, is
produced in the circulation from angiotensinogen (AGT)
because of the action of the enzymes renin and angiotensin-
converting enzyme. In addition, it has become evident that
several components of RAS are present in a variety of tissues,
including adipose tissue and skeletal muscle (reviewed in
Reference 4), implying that these tissues have the ability to
produce Ang II.
There is substantial evidence that circulating RAS compo-
nents are increased in (hypertensive) obese subjects.5–8 In line
with this, it has been shown that weight loss reduces systemic
RAS activity.5 These findings indicate that obesity is respon-
sible for increased systemic RAS activity and suggest that
RAS components that are expressed in adipose tissue may
also be secreted into the circulation and exert endocrine
effects. This idea is supported by a study in wild-type mice,
AGT knockout (AGT$/$) mice, and mice specifically ex-
pressing AGT in adipose tissue, showing that adipocytes are
a considerable source of plasma AGT.9
Although less is known about the regulation of RAS, there
is evidence that RAS activity is under control of the sympa-
thetic nervous system. It has been shown that !-adrenergic
stimulation increases plasma renin activity (PRA) in humans.10
Furthermore, it has been shown that local !-adrenergic stimula-
tion evokes release of renin and Ang II from forearm vessels in
essentially hypertensive subjects.11,12 Until now, the effect of
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!-adrenergic stimulation on local RAS in adipose tissue has not
been investigated in vivo in humans.
The objective of the present study was to investigate whether
abdominal subcutaneous adipose tissue and skeletal muscle
release Ang II and/or AGT into the circulation in vivo in lean
and obese subjects. Second, the effects of !-adrenergic stimula-
tion on systemic RAS activity and release of Ang II and AGT
from adipose tissue and skeletal muscle were investigated in
these subjects.
Methods
Subjects
Thirteen lean (body mass index #25 kg/m2) and 10 obese (body
mass index %30 kg/m2), nonsmoking normotensive male subjects
participated in this study. Physical characteristics of the subjects are
summarized in the Table. Body weight and body fat percentage
(hydrostatic weighing) were determined as has been described
previously.13 All of the subjects were in good health as assessed by
medical history, weight stable for "6 months before investigation,
free of any medication, and spent #3 hours per week in organized
sports activities. The medical-ethical committee of Maastricht Uni-
versity approved the study protocol, and all of the subjects gave their
written informed consent before participating in the study.
Protocol
All of the subjects were asked to refrain from drinking alcohol and to
perform no strenuous exercise for a period of 24 hours before the study.
Subjects came to the laboratory by car or bus in the morning after an
overnight fast. Four cannulas were inserted before the start of the
experiment. Arterialized venous blood was obtained through a cannula
inserted retrogradely into a superficial dorsal hand vein. The hand was
warmed in a hot box, which was maintained at 60°C to achieve adequate
arterialization.14 In the same arm, a second cannula was inserted in a
forearm antecubital vein for the infusion of the nonselective
!-adrenergic agonist isoprenaline (ISO). In the contralateral arm, a third
catheter was introduced retrogradely in an antecubital vein of the
forearm for sampling of deep venous blood, draining skeletal muscle.
Finally, after identification of the veins with a fiber-optic light source, a
10-cm 22-gauge catheter (central venous catheter kit, Seldinger tech-
nique, Becton Dickinson BV) was introduced anterogradely over a
guide wire into one of the superficial veins on the anterior abdominal
wall and threaded toward the groin, so that its tip lay just superior to the
inguinal ligament, to obtain adipose tissue venous blood.15 This pro-
vides the drainage from the adipose tissue of the abdomen, uncontam-
inated by muscle drainage and with only a minor contribution from
skin.15–17 The adipose vein was kept patent by continuous saline (9 g/L
NaCl) infusion at a rate of 80 mL/h. The subjects rested in a supine
position for the duration of the study.
Ang II and AGT Release Into the Circulation
Circulating Ang II and AGT concentrations and net release of these
RAS components from abdominal subcutaneous adipose tissue and
skeletal muscle into the circulation were investigated in vivo under
baseline conditions and during intravenous infusion of ISO. After a
120-minute baseline period, ISO was intravenously infused at a rate
of 20 ng kg fat free mass$1 min$1 for 60 minutes.18 During the
experiment, heart rate was recorded continuously by means of a
3-lead ECG. When heart rate increased %40 bpm or in case of ECG
irregularities, ISO infusion was discontinued (n"2, 1 lean and 1
obese subject).
Blood samples were taken simultaneously from the arterialized
vein, the adipose vein, and the deep forearm vein while the hand
circulation was occluded at 3 baseline time points (t90, t105, and
t120) and 3 time points during the last 30 minutes of ISO infusion
(t160, t175, and t190). Adipose tissue blood flow was monitored
continuously using 133xenon washout,19 and forearm blood flow
(FBF) was measured at the same time points that blood was collected
using venous occlusion plethysmography,20 as has been described
previously. Plasma flow was calculated as tissue blood flow&
(1$hematocrit), with hematocrit expressed as a fraction. Ang II and
AGT fluxes across adipose tissue and muscle were calculated from
the arteriovenous concentration differences multiplied by tissue
plasma flow. Positive fluxes indicate net uptake from plasma,
whereas negative fluxes indicate net tissue release.
Analyses
Blood samples were collected into syringes containing either EDTA
or Ang II buffer21 and immediately transferred into ice-chilled
polypropylene tubes. Blood samples were then centrifuged (1000g,
4°C, 10 minutes), and plasma was immediately frozen in liquid
nitrogen and stored at $80°C until analysis. A small proportion of
blood was used for measurement of oxygen saturation to ensure
adequate arterialization (ABL 510, Radiometer).
Ang II was measured by a standard radioimmunoassay (Peninsula
Laboratories Europe) after C-18 Sep-Pak (Waters-Millipore) extrac-
tion of the peptide. Intra-assay and interassay coefficients of varia-
tion were 4.6% and 7.7%, respectively. AGT was measured by
radioimmunoassay of Ang I after complete hydrolysis with an excess
of human renin. Briefly, 25 $L of plasma prediluted 1:100 in assay
buffer was incubated together with 470 $L of 0.15 mol/L citrate–
phosphate buffer (pH 5.7) containing 0.025 mol/L of Na2-EDTA, 1.0
g/L of BSA, and 50 ng of human recombinant renin with 5 $L of
PMSF for 60 minutes at 37°C. Reactions were stopped by incubation
on ice, and the amount of Ang I generated was measured. AGT
concentration is expressed as nanograms of Ang I per milliliter. Active
renin was measured by a standard radioimmunometric assay (Renin III
generation, Schering CIS Bio International). Intra-assay and interassay
coefficients of variation were 2.9% and 7.6%, respectively. Plasma
glucose concentration was measured using a standard enzymatic method
(ABX Pentra Glucose HK CP, Radiometer). Plasma insulin concentra-
tion was measured by a specific double antibody radioimmunoassay for
human insulin (Linco Research Inc).
Statistical Analysis
Data are presented as mean!SEM. Differences between lean and
obese subjects were compared using the Mann–Whitney test. The
effects of !-adrenergic stimulation within groups were tested using
Wilcoxon signed-rank test. Calculations were done using SPSS 10.1
for Windows. P#0.05 was considered to be statistically significant.
Results
By definition, obese subjects had a significantly higher body
weight, body mass index, and body fat percentage compared
with lean subjects, as summarized in the Table.
Adipose Tissue Blood Flow and FBF
Basal adipose tissue blood flow was significantly higher in
lean compared with obese subjects (2.2!0.2 versus 1.4!0.2
Subject Characteristics
Characteristic Lean (n"13) Obese (n"10)
Age, y 49!3 54!3
Weight, kg 75.2!1.5 101.9!3.2†
BMI, kg/m2 23.0!0.5 31.9!0.6†
Body fat, % 20.2!1.0 31.7!0.5†
Waist, cm 87.0!1.4 111.5!2.3†
SBP, mm Hg 126.1!3.4 136.6!4.3
DBP, mm Hg 77.3!2.4 85.0!2.7
Fasting glucose, mmol/L 5.3!0.1 5.5!0.2
Fasting insulin, mU/L 7.2!0.6 13.9!1.2*
BMI indicates body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure. Values are mean!SEM.
*P"0.001, †P#0.001 vs lean.
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mL 100 g tissue$1 min$1, P"0.03, respectively), whereas
basal FBF was comparable in lean and obese subjects (2.9!0.2
versus 2.4!0.3 mL 100 mL forearm tissue$1 min$1, P"0.28,
respectively; Figure 1).
!-Adrenergic stimulation induced a significant increase in
tissue blood flows. Adipose tissue blood flow significantly
increased during !-adrenergic stimulation compared with
baseline in both lean (6.3!1.2 versus 2.2!0.2 mL 100 g
tissue$1 min$1, P"0.008, respectively) and obese subjects
(3.6!0.6 versus 1.6!0.2 mL 100 g tissue$1 min$1, P"0.03,
respectively). Furthermore, FBF was significantly elevated
during !-adrenergic stimulation in both lean (4.6!0.4 versus
2.9!0.2 mL 100 mL forearm tissue$1 min$1; P"0.002) and
obese subjects (3.5!0.3 versus 2.5!0.3 mL 100 mL forearm
tissue$1 min$1; P"0.01; Figure 1). The increase in adipose
tissue blood flow and FBF during !-adrenergic stimulation
was not significantly different between groups (P"0.22 and
P"0.46, respectively).
Plasma Ang II and AGT Concentrations
Basal plasma Ang II concentrations were not significantly
different between lean (n"13) and obese (n"10) subjects
(8.2!1.3 versus 9.9!0.9 pmol/L, P"0.21, respectively).
!-Adrenergic stimulation had no significant effect on circu-
lating Ang II concentrations in lean (n"12) subjects
(P"0.13) but increased Ang II concentrations in obese (n"9)
subjects (baseline: 10.2!0.9 versus ISO: 12.6!1.5 pmol/L;
P"0.05), resulting in significantly higher Ang II concentra-
tions during !-adrenergic stimulation in obese compared with
lean subjects (P"0.04; Figure 2A). Plasma AGT concentra-
tions were not significantly different between lean and obese
subjects at baseline (617.1!107.0 versus 657.9!122.4 ng of
Ang I per milliliter, P"0.71, respectively) and during
!-adrenergic stimulation (569.9!111.1 versus 656.2!136.4
ng of Ang I per milliliter, P"0.59, respectively; Figure 2B).
PRA
Basal PRA was comparable between lean and obese subjects
(12.8!1.8 versus 10.8!1.7 mU/L, P"0.77, respectively).
PRA was significantly increased from baseline during !-
adrenergic stimulation in lean (21.3!2.8 mU/L; P"0.002)
and obese subjects (21.1!4.6 mU/L; P"0.01; Figure 2C).
The increase in PRA during !-adrenergic stimulation was not
different between groups (P"0.94).
Ang II and AGT Fluxes Across Abdominal
Subcutaneous Adipose Tissue
Under baseline conditions, no significant net uptake or re-
lease of Ang II across abdominal subcutaneous adipose tissue
Figure 1. Adipose tissue (lean, n"9; obese, n"7) and muscle
blood flow (lean, n"13; obese, n"10) under baseline conditions
and during !-adrenergic stimulation (ISO infusion). *P#0.05 vs
obese, #P#0.05 vs baseline, ##P#0.01 vs baseline. Values are
mean!SEM.
Figure 2. (A) Plasma Ang II concentrations, (B) plasma AGT
concentrations, and (C) plasma renin activity in lean (n"13) and
obese (n"10) subjects under baseline conditions and during
!-adrenergic stimulation (ISO infusion; n"12 and n"9, respec-
tively). *P#0.05 vs lean, #P"0.01 vs baseline, ##P#0.01 vs
baseline. Values are mean!SEM.
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could be detected in lean (1.18!0.84 fmol 100 g tissue$1
min$1, P"0.14 versus zero flux) and obese subjects
(0.83!0.41 fmol 100 g tissue$1 min$1, P"0.18 versus zero
flux; Figure 3A). Net Ang II fluxes across adipose tissue were
not significantly different from baseline during !-adrenergic
stimulation in lean (P"0.52) and obese subjects (P"0.75;
Figure 3A).
No significant baseline net uptake or release of AGT across
abdominal subcutaneous adipose tissue was observed in lean
($11.6!16.1 ng Ang I 100 g tissue$1 min$1, P"0.59 versus
0 flux) and obese subjects (29.6!12.0 ng Ang I 100 g tissue$1
min$1, P"0.06 versus zero flux; Figure 3B). !-Adrenergic
stimulation induced a shift from a tendency for AGT uptake
toward net AGT release across abdominal subcutaneous
adipose tissue, which was statistically significant in obese
(baseline: 34.8!12.8 versus ISO: $75.5!50.6 ng Ang I
100 g tissue$1 min$1; P"0.03) but not in lean subjects
(P"0.77; Figure 3B).
Ang II and AGT Fluxes Across Skeletal Muscle
There was no detectable net uptake or release of Ang II across
skeletal muscle under baseline conditions in lean (0.53!0.57
fmol 100 g tissue$1 min$1, P"0.55 versus zero flux) and
obese subjects ($0.78!0.44 fmol 100 g tissue$1 min$1,
P"0.07 versus zero flux; Figure 3A). !-Adrenergic stimula-
tion had no significant effect on net Ang II fluxes across
muscle in lean (P"0.21) and obese subjects (P"0.59; Figure
3A).
No AGT release across muscle was detectable at baseline
in lean ($10.4!38.7 ng Ang I 100 g tissue$1 min$1, P"0.46
versus zero flux) and obese subjects (29.1!17.3 ng Ang I
100 g tissue$1 min$1, P"0.16 versus zero flux; Figure 3B).
However, !-adrenergic stimulation evoked release of AGT
across muscle in lean ($130.0!61.7 ng Ang I 100 g tissue$1
min$1, P"0.05 versus zero flux) and obese subjects
($94.7!45.0 ng Ang I 100 g tissue$1 min$1, P"0.02 versus
zero flux), with no significant differences between groups
(Figure 3B).
Discussion
There is substantial evidence that obesity is a prime cause of
hypertension, cardiovascular disease, and insulin resistance in
obese individuals.1,22 Many studies suggest that RAS in
adipose tissue may play an important role in the development
of obesity-associated hypertension and insulin resistance.4
We hypothesized that locally generated RAS components in
adipose tissue and/or skeletal muscle are released into the
circulation and may act as endocrine hormones. Furthermore,
the effects of !-adrenergic stimulation on systemic RAS
activity and local Ang II and/or AGT release from adipose
tissue and skeletal muscle were examined. We demonstrated
that plasma Ang II concentrations are increased during
!-adrenergic stimulation in obese but not in lean subjects.
Increased release of AGT from adipose tissue and skeletal
muscle in obese subjects during !-adrenergic stimulation
may explain this finding.
Circulating RAS Components
We found that fasting plasma Ang II and AGT concentrations
are comparable between lean and obese subjects. The com-
parable plasma Ang II concentrations between both groups
are in line with previous findings.5 In contrast, most studies
have shown increased plasma AGT concentrations in obese
subjects.5–8 However, the increased AGT concentrations in
obese subjects were not significantly different in lean and
obese subjects after adjustment for blood pressure.8 Although
body mass index was positively associated with blood pres-
sure in the present study (data not shown), the blood pressure
difference was not significant between groups, which may
explain the comparable plasma AGT concentrations in lean
and obese subjects. !-Adrenergic stimulation increased
plasma Ang II concentrations in obese but not in lean
subjects, whereas plasma AGT concentrations remained un-
changed in both groups.
It has been demonstrated previously that !-adrenergic
stimulation increases PRA in humans.10,23–25 Until now, it
was unknown whether the effect of !-adrenergic stimulation
on PRA is comparable between lean and obese subjects. We
show that PRA was increased to a similar extent in both
groups of subjects during intravenous infusion of the non-
selective !-adrenergic agonist ISO. These data suggest that
the increase in PRA cannot explain the elevated plasma
Figure 3. (A) Ang II fluxes and (B) AGT fluxes across abdominal
subcutaneous adipose tissue (lean, n"9; obese, n"7) and skel-
etal muscle (lean, n"13; obese, n"10) under baseline condi-
tions and during !-adrenergic stimulation (ISO infusion). Positive
fluxes indicate net uptake from plasma, whereas negative fluxes
indicate net tissue release. *P#0.05 vs baseline, #P#0.05 vs 0
flux. Values are mean!SEM.
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Ang II concentration in obese subjects during !-adrenergic
stimulation.
Endocrine Function of the Local RAS in Adipose
Tissue and Skeletal Muscle
Because adipose tissue exerts endocrine functions26 and RAS
components are expressed in human adipose tissue,4,5 it is
tempting to speculate that secretion of RAS components from
adipose tissue could play a role in obesity-related complica-
tions, including hypertension. A recent report demonstrated
that 5% weight loss was accompanied by decreased systemic
RAS activity and blood pressure,5 which further suggests that
obesity is responsible for increased systemic RAS activity.
The concept that RAS components that are expressed in
adipose tissue may exert endocrine effects is supported by a
study where wild-type mice were compared with AGT$/$
mice and with transgenic mice specifically expressing AGT
in adipose tissue either on the AGT$/$ background or on the
wild-type background. It was shown that adipocytes are a
considerable source of plasma AGT, which may explain the
observed elevated blood pressure in the transgenic animals.9
Likewise, a local Ang II generating system is present in
skeletal muscle,27 and this tissue may, therefore, also contrib-
ute to circulating concentrations of RAS components.
Determination of Ang II fluxes across abdominal subcuta-
neous adipose tissue and muscle under baseline conditions
and during !-adrenergic stimulation revealed that there was
no detectable net uptake or release of Ang II across adipose
tissue and skeletal muscle in lean and obese subjects under
both conditions. Therefore, Ang II secretion from these
tissues cannot explain the increased Ang II concentrations
observed in obese subjects during !-adrenergic stimulation.
Because it is well established that Ang II is produced by
human adipocytes,28 our data suggest that locally produced
Ang II in adipose tissue acts as an autocrine and/or paracrine
hormone and does not exert endocrine effects. The present
findings seem to be in contrast with a recent study demon-
strating Ang II secretion from adipose tissue in vivo in
overweight/obese subjects.29 However, when measuring Ang
II, it is crucial to use Ang II buffer to eliminate breakdown,
as well as further production, of Ang II during processing of
the samples.21,30 In the study by Harte et al,29 these strict
methodologic procedures were not taken into account. This
may explain the reported supraphysiological Ang II concen-
trations and raises some doubt on the validity of these
findings. Our muscle data are in line with previous findings
demonstrating that Ang II is not released from skeletal
muscle under baseline conditions in hypertensive patients.12
However, local !-adrenergic stimulation evoked renin and
Ang II release from forearm vessels in these patients,11,12
which seems to be in contradiction with our findings of no
detectable Ang II release. Several explanations may be respon-
sible for this apparent discrepancy. First, local !-adrenergic
stimulation (intrabrachial infusion)12 may have caused a more
pronounced stimulus compared with intravenous infusion of a
!-adrenergic agonist in the present study.18 This is supported
by the fact that the increase in FBF during local !-adrenergic
stimulation was more pronounced than the elevation in FBF
observed in the present study. Second, they studied hyperten-
sive and moderately sodium-depleted subjects,11,12 character-
ized by increased activation of the RAS,31 whereas the
subjects in the present study were normotensive and main-
tained their normal dietary sodium intake. Third, the release
of renin and Ang II across skeletal muscle during local
!-adrenergic stimulation rapidly declined after 5 to 10 min-
utes,12 indicating that this system might represent a short-term
control mechanism. Because in the present study Ang II
release was assessed during the last 30 minutes of a 1-hour
ISO infusion, downregulation of local Ang II generation may
have occurred, resulting in undetectable Ang II release from
muscle.
Furthermore, we did not find AGT release across adipose
tissue and skeletal muscle under baseline conditions. How-
ever, AGT was released from skeletal muscle in lean (ten-
dency) and obese subjects during !-adrenergic stimulation. In
addition, a significant shift toward net AGT secretion from
adipose tissue was observed in obese subjects during ISO
infusion. Net AGT release across adipose tissue and skeletal
muscle shows high interindividual variation in lean subjects.
Importantly, mean net AGT release across adipose tissue
during !-adrenergic stimulation in lean subjects is largely
explained by 1 individual showing high AGT release across
adipose tissue. If we had decided to leave this individual out
of the statistical analysis, the mean value for net AGT release
across adipose tissue would have been slightly positive
(direction of net AGT uptake), and the SE would have been
much smaller (from $97.1!114.3 to 15.6!21.2 ng of Ang I
100 g tissue$1 min$1). However, there was no reason to leave
this subject out of the statistical analysis. Considering the
increased adipose tissue and skeletal muscle mass in obese
compared with lean subjects (Table), these data suggest that
at the whole body level AGT release from adipose tissue and
skeletal muscle may contribute to the increased plasma Ang
II concentrations during !-adrenergic stimulation in obese
subjects. Rapid conversion of AGT that is released from
adipose tissue and skeletal muscle into Ang I and subsequent
conversion into Ang II may explain why plasma AGT
concentrations were not increased during !-adrenergic stim-
ulation. An additional explanation may be that increased Ang
II production and secretion from other tissues than abdominal
subcutaneous adipose tissue and skeletal muscle, such as the
kidney and liver, is responsible for this elevation in Ang II
concentration. In addition, visceral fat may produce and
secrete Ang II and/or AGT, because AGT mRNA expression
is increased in visceral compared with subcutaneous adipose
tissue.32,33
Perspectives
The present findings demonstrate that net Ang II uptake or
release across abdominal subcutaneous adipose tissue and
skeletal muscle is undetectable under baseline conditions
and during !-adrenergic stimulation. Because Ang II is pro-
duced by human adipocytes, our data suggest that locally
produced Ang II in adipose tissue acts as an autocrine and/or
paracrine hormone. In contrast, AGT is released from adipose
tissue and skeletal muscle in obese subjects during !-adrenergic
stimulation, and this may contribute to the observed increase in
plasma Ang II concentrations during !-adrenergic stimulation in
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these subjects. Although we recognize that !-adrenergic stimu-
lation is different from sympathetic nervous system activity
(resulting in %-adrenergic and !-adrenergic stimulation) and we
have not measured sympathetic nervous system activity in the
present study, it is tempting to postulate that activation of the
local adipose tissue and muscle RAS is an important mechanism
by which increased sympathetic nervous system activity may
contribute to the development of hypertension in obesity. Our
findings further suggest that angiotensin-converting enzyme
inhibitors may exert their beneficial effects, at least partly, by
decreasing the conversion of adipose tissue and muscle-
derived AGT, thereby reducing Ang II production.
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